Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Killock

Showing results (221-230 of 304) with videos related to

Pageof 31
Sort By:
Nature Reviews. Clinical Oncology|June 24, 2022
HSP90 inhibition improves GIST survivalDavid Killock
Nature Reviews. Clinical Oncology|May 24, 2024
Adding ibrutinib to frontline therapy improves outcomes in transplant-eligible patients with MCLDavid Killock
Nature Reviews. Clinical Oncology|October 28, 2025
HER2-directed therapy improves urothelial cancer outcomesDavid Killock
Nature Reviews. Clinical Oncology|February 22, 2024
Adjuvant chemotherapy improves OS in UTUCDavid Killock
Nature Reviews. Clinical Oncology|April 18, 2024
ALND can be safely omitted for patients with sentinel-node macrometastasesDavid Killock
Nature Reviews. Clinical Oncology|April 20, 2022
Pembrolizumab reduces recurrence risk in stage II melanomaDavid Killock
Nature Reviews. Clinical Oncology|November 26, 2024
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJCDavid Killock
Nature Reviews. Clinical Oncology|January 3, 2025
cfDNA screening for fetal aneuploidy facilitates maternal cancer detectionDavid Killock
Nature Reviews. Clinical Oncology|January 3, 2025
Imlunestrant shows efficacy both with and without abemaciclibDavid Killock
Nature Reviews. Clinical Oncology|September 27, 2017
Drug therapy: Moving on up - from stage IV into stage IIIDavid Killock
Pageof 31

Showing results (221-230 of 304) with videos related to

Sort By:
Pageof 31
Nature Reviews. Clinical Oncology|June 24, 2022
HSP90 inhibition improves GIST survivalDavid Killock
Nature Reviews. Clinical Oncology|May 24, 2024
Adding ibrutinib to frontline therapy improves outcomes in transplant-eligible patients with MCLDavid Killock
Nature Reviews. Clinical Oncology|October 28, 2025
HER2-directed therapy improves urothelial cancer outcomesDavid Killock
Nature Reviews. Clinical Oncology|February 22, 2024
Adjuvant chemotherapy improves OS in UTUCDavid Killock
Nature Reviews. Clinical Oncology|April 18, 2024
ALND can be safely omitted for patients with sentinel-node macrometastasesDavid Killock
Nature Reviews. Clinical Oncology|April 20, 2022
Pembrolizumab reduces recurrence risk in stage II melanomaDavid Killock
Nature Reviews. Clinical Oncology|November 26, 2024
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJCDavid Killock
Nature Reviews. Clinical Oncology|January 3, 2025
cfDNA screening for fetal aneuploidy facilitates maternal cancer detectionDavid Killock
Nature Reviews. Clinical Oncology|January 3, 2025
Imlunestrant shows efficacy both with and without abemaciclibDavid Killock
Nature Reviews. Clinical Oncology|September 27, 2017
Drug therapy: Moving on up - from stage IV into stage IIIDavid Killock
Pageof 31